Fortress Biotech Reports Record Second Quarter 2021 Financial Results and Recent Corporate Highlights Aug 16, 2021
Mustang Bio Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights Aug 16, 2021
Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Aug 02, 2021
Checkpoint Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference Jul 08, 2021
Journey Medical Corporation Enters into a Definitive Agreement with Dr. Reddy’s Laboratories Ltd. to Develop and Commercialize DFD-29 for the Treatment of Rosacea Jun 30, 2021